The Tandem Mobi mobile app is designed to connect with the insulin pump, enabling users in managing their diabetes from a compatible smartphone. Credit: Tandem Diabetes Care / Business Wire.

The US Food and Drug Administration (FDA) has granted clearance for the Android version of Tandem Diabetes Care’s Tandem Mobi mobile application.

The app is designed to securely connect with the Tandem Mobi insulin pump, enabling users to manage diabetes from a compatible smartphone, now including Android devices.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Tandem Mobi operates using Control-IQ+ technology, which has shown improvements from the first day of use.

It can securely integrate with the Tandem Source platform, supporting communication between healthcare providers and patients to assist in treatment decisions.

The Tandem Mobi pump is indicated for subcutaneous insulin delivery at set or variable rates for people with diabetes mellitus who need insulin and is cleared for use in individuals aged two years and older.

According to the company, the pump can communicate with compatible digital devices, including automated dosing software.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A limited release of the Android app is planned for next month, with commercial availability targeted for early 2026.

Once available, users will be able to download the app from the Google Play Store on compatible models such as Google Pixel 6 through 10 and Samsung Galaxy S21 through S25, with a list of supported devices to be released ahead of launch.

Tandem Diabetes Care CEO and president John Sheridan said: “We’re excited to bring Tandem Mobi and the best-in-class outcomes of Control-IQ+ to Android users.

“This latest integration gives Android users access to the life-changing benefits of Control-IQ+ on a system that emphasises convenience, discretion, and customisation.”

In June 2025, Tandem Diabetes Care announced that its t:slim X2 insulin pump had become compatible with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact